Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial

Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial

Détails bibliographiques
Auteurs principaux:	Bekker, P, Petryka, R, Vanasek, T, Niv, Y, Marlicz, K, Haagen-Nielsen, O, Dahelrup, J, Dotan, I, Compel, V, Keshav, S, Schall, T
Format:	Conference item
Publié:	2008

Documents similaires

PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
par: Keshav, S, et autres
Publié: (2007)

Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
par: Bekker, P, et autres
Publié: (2007)

PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
par: Bekker, P, et autres
Publié: (2009)

PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
par: Keshav, S, et autres
Publié: (2009)

A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
par: Satish Keshav, et autres
Publié: (2013-01-01)

Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
par: Keshav, S, et autres
Publié: (2007)

Traficet-EN, an Oral CCR9-Specific Antagonist, induces high levels of remission in the open-label Phase of PROTECT-1 in Crohn's Disease
par: Bekker, P, et autres
Publié: (2008)

Traficet-EN, an oral CCR9-specific antagonist, induces high levels of remission in the open-label phase of PROTECT-1 in Crohn's disease
par: Bekker, P, et autres
Publié: (2008)

MEDI 167-Discovery of the highly potent, selective and orally bioavailable CCR9 antagonist CCX282-B
par: Ungashe, S, et autres
Publié: (2008)

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
par: Walters, M, et autres
Publié: (2010)

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity.
par: Kathleen M C Sullivan, et autres
Publié: (2023-01-01)

Identification and Expression Profiling Analysis of the Cation/Ca2+ Exchanger (CCX) Gene Family: Overexpression of SlCCX1-LIKE Regulates the Leaf Senescence in Tomato Flowering Phase
par: Jiao Li, et autres
Publié: (2021-06-01)

Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
par: Pirow Bekker, et autres
Publié: (2016-01-01)

Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
par: Pirow Bekker, et autres
Publié: (2019-01-01)

A Node-Expressed Transporter OsCCX2 Is Involved in Grain Cadmium Accumulation of Rice
par: Xiaohua Hao, et autres
Publié: (2018-04-01)

Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype
par: Adams, P, et autres
Publié: (2018)

Influence of smoking on colonic gene expression profile in Crohn's disease.
par: Ole Haagen Nielsen, et autres
Publié: (2009-01-01)

Expression of CCR8 and CCX-CKR on Basophils in Chronic Urticaria Is Amplified by IgE-Mediated Activation
par: Ewa A. Bartko, et autres
Publié: (2023-05-01)

The Prevalence of Crohn’s Disease in the Israeli Kibbutz Population
par: Yaron Niv
Publié: (1991-01-01)

Capsule endoscopy in the diagnosis of Crohn’s disease
par: Niv Y
Publié: (2013-05-01)

Editorial 28.2
par: Hormindo Pereira de Souza Junior, et autres
Publié: (2019-09-01)

Evidence for impaired CARD15 signalling in Crohn's disease without disease linked variants.
par: Jakob Benedict Seidelin, et autres
Publié: (2009-11-01)

Emerging concepts in non-invasive monitoring of Crohn’s disease
par: Wojciech Marlicz, et autres
Publié: (2018-04-01)

Medical management of Crohn's disease.
par: Cummings, JR, et autres
Publié: (2008)

Mat 282- Pengiraan Kejuruteraan I
par: PPSM, Pusat Pengajian Sains Matematik
Publié: (2004)

Contribuíram nesta edição (28.2)
Publié: (2020-06-01)

Contribuíram nesta edição (28.2)
Publié: (2020-06-01)

Administering the Oath at the 282 NBC Protection Troops Training Centre
Publié: (2023-07-01)

High-Pressure Cooling in Finishing Turning of Haynes 282 Using Carbide Tools: Haynes 282 and Inconel 718 Comparison
par: Antonio Díaz-Álvarez, et autres
Publié: (2021-11-01)

The Oral manifestation of Crohn's disease
par: Gabriela Broniec, et autres
Publié: (2024-09-01)

Oral manifestations of Crohn's disease
par: Marković Ljiljana, et autres
Publié: (2004-01-01)

282 COLPOSUSPENSION, DOES SUTURE MATERIAL MATTER?
par: S Kay, et autres
Publié: (2022-06-01)

Dynamic strain aging in Haynes 282 superalloy
par: Hörnqvist Magnus, et autres
Publié: (2014-01-01)

Finishing Turning of Ni Superalloy Haynes 282
par: José Díaz-Álvarez, et autres
Publié: (2018-10-01)

IgG subclass levels in referred hemochromatosis probands with HFE p.C282Y/p.C282Y
par: James C. Barton, et autres
Publié: (2024-01-01)

IgG subclass levels in referred hemochromatosis probands with HFE p.C282Y/p.C282Y.
par: James C Barton, et autres
Publié: (2024-01-01)

Community Connectors (CCx): the strategies employed by peer to peer connectors to foster relationships with early years caregivers to improve universal early child health and development
par: C. F. Mills, et autres
Publié: (2021-03-01)

Comparing ANI-2x, ANI-1ccx neural networks, force field, and DFT methods for predicting conformational potential energy of organic molecules
par: Mozafar Rezaee, et autres
Publié: (2024-05-01)

Draft genome sequence of the model naphthalene-utilizing organism Pseudomonas putida OUS282
par: Tay, Martin, et autres
Publié: (2019)

MAT 282 - Pengiraan Kejuruteraan I - Oktober 2004
par: PPSM, Pusat Pengajian Sains Matematik
Publié: (2004)